Fund moves
4.8%Stake · was 7.4%
The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
RVTY · NYSE · Health Care Equipment
Revvity (RVTY) · oqro.io/stocks/RVTY · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
No open-market purchase by an insider of Revvity was filed in the last 90 days. The latest on record was on Nov 26, 2012.
Since 2006, Revvity insiders reported 16 open-market purchases and 821 sales on Forms 4 and 5, with purchases in 3 different years, most recently 2012.
In the last 90 days, 3 insiders of Revvity (RVTY) reported 3 open-market sales worth $1.28M in total on SEC Form 4. The largest seller by value was Tajinder S Vohra, with $1.03M. Many insider sales follow a plan set in advance or cover taxes on stock awards; the filing says what was sold, not the reason.
Yes. Members of Congress disclosed 6 trades in Revvity (RVTY) in the last 12 months, each reported as a value range on a periodic transaction report. The most recent is from Rep. Gilbert Ray Cisneros Jr. (CA31).
Revvity's next results are expected on Feb 1, 2027, after the market closes. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
$152.43+4.64 (+3.14%)
Close of Nov 18, 2026, vs Nov 17 · end-of-day, not a live quote
+63.8% (+$59.37) from Nov 18, 2025 to Nov 18, 2026 · adjusted daily closes
Adjusted close went from $93.06 on Nov 18, 2025 to $152.43 on Nov 18, 2026 (+63.8%). Disclosed in this range: 1 insider trade, 16 pre-arranged insider sales, 6 Congress trades, and 12 13F position changes for 4 quarters ending in it.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Health Care Equipment company based in Waltham, Massachusetts.
Last 12 months
+63.8%
Market value
$17B
S&P 500 +10.6% over the same dates. Prices adjusted for splits and dividends.
Short interest: 6.53M shares sold short (5.8% of shares outstanding), +2.1% vs the previous count, 3.9 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.
Revenue
$729M
+4.3% vs the same quarter a year earlier
Free cash flow, last 12 months
$590M
This quarter $152M, a year earlier $120M
Net debt
$2.04B
Debt $2.63B, cash $593M, at Oct 4, 2026
Net income, last 12 months
$253M
Operating profit covers interest 4x
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 3, 2026.
Revenue, fiscal 2025
$2.86B
+3.7% vs the year before
Net income, fiscal 2025
$241M
As reported in the annual filing
Shares outstanding
112M
As of Nov 6, 2026
In fiscal 2025 the company spent $821M buying back its own shares and $32.8M on dividends. Cash actually paid, from its cash-flow statement.
New federal contracts from the last 12 months add up to 0.07% of that revenue. Contract money is usually earned over several years, so this is a size comparison, not a share of sales.
Fund moves
The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
Fund moves
From a 13F filed Nov 16, 2026 covering holdings at Sep 30, 2026 — a quarter-end snapshot, not a live trade.
Congress
Traded Oct 27 · disclosed 14 days later
Since the trade −5.8% · S&P 500 −5.1% · to Nov 18
Traded Sep 3 – Sep 9, 2026 · disclosed 33 to 39 days later · largest single trade $15,001–$50,000
Sep 9, 2026$15,001–$50,000
DetailsOfficial recordSep 3, 2026$1,001–$15,000
DetailsOfficial recordPrices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
On the public record for Revvity over the 12 months to Nov 18, 2026: 1 FDA record and 5 executive contributions.
Against the S&P 500 over the year
Since Nov 14, 2025, RVTY is up 59.4% and the index fund is up 9.0%: 50 points ahead of the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much RVTY moves
End-of-day prices. These figures describe the past year and say nothing about what comes next.
Insiders of Revvity reported 16 open-market purchases and 821 sales since 2006; purchases in 3 different years, most recently 2012.
| Year | Bought | Sold |
|---|---|---|
| 2026 | — | $5.97M17×17 trades |
| 2025 | — | $2.9M11×11 trades |
| 2024 | — | $9.3M25×25 trades |
| 2023 | — | $2.38M10×10 trades |
| 2022 | — | $12.3M31×31 trades |
| 2021 | — | $11.2M35×35 trades |
| 2020 | — | $7.16M11×11 trades |
| 2019 | — | $7.26M12×12 trades |
| 2018 | — | $49.9M25×25 trades |
| 2017 | — | $25.2M21×21 trades |
| 2016 | — | $23M17×17 trades |
| 2015 | — | $30.5M26×26 trades |
| 2014 | — | $28.4M36×36 trades |
| 2013 | — | $14.6M19×19 trades |
| 2012 | $2.6K1×1 trade | $8.45M21×21 trades |
| 2011 | $2.4K1×1 trade | $1.55M8×8 trades |
| 2010 | — | $10.3M10×10 trades |
| 2009 | — | $5.72M18×18 trades |
| 2008 | — | $49.1M193×193 trades |
| 2007 | — | $30.1M242×242 trades |
| 2006 | $1.01M14×14 trades | $1.21M33×33 trades |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Written by software from the filings listed below · Oct 26, 2026
4 more points, with the facts they come from, are in OQRO Pro.
Sign up freeT. Rowe Price Associates, Inc.
Schedule 13G: passive · filed Oct 7, 2026 · 13.2M shares
T. Rowe Price Investment Management, Inc.
Schedule 13G: passive · filed Sep 8, 2026 · 10.3M shares
Vanguard Capital Management
Schedule 13G: passive · filed Apr 30, 2026 · 8.33M shares
JANUS HENDERSON GROUP Ltd.
Schedule 13G: passive · filed Nov 16, 2026 · 7.39M shares
Anyone owning more than 5% must file within days. Structured filings have existed since December 2024, so older stakes that were never amended may be missing.
Last results
Nov 3, 2026
Within the 30 days after it, until Dec 3, 2026
Next results, expected
Feb 1, 2027
after the market closes; the date can move until the company confirms it
Purchases after results
Not enough history
From Revvity's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Revvity's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
0 certified in FY2026 Q3, vs 3 a year earlier.
Labor condition applications for H-1B workers certified by the Department of Labor, counted by decision date (FY2026 Q3: Apr 1, 2026 to Jun 30, 2026, the latest quarter published). A certified application is a step before a visa petition, not a hire or a visa, and one application can cover several positions. Matched by employer ID number or name.
Short sale volume: 42.0% of the volume reported to FINRA over the last 20 trading days was marked short, below its 1-year average of 57.7%. FINRA daily files, to Nov 18, 2026.
Fails to deliver: 9,616 shares (about $1.47M) were not delivered on time for settlement on Oct 7, 2026. SEC fails-to-deliver data.
Short sale volume is not short interest. It counts trades marked short, including market makers selling short to fill buy orders, so it is a share of daily trading, not a count of bets against the stock. Fails to deliver have many causes, including processing delays, and are often resolved within days.
1 approval or clearance and 0 recalls recorded by the FDA for this company and its listed subsidiaries.
From openFDA: Drugs@FDA (new applications and new uses), device 510(k) and PMA decisions, and FDA enforcement reports. Class I recalls are the most serious, Class III the least. Most recalls are started by the company itself. Labeling and manufacturing changes are not listed.